Aug 2026· European Heart Journal, Supplement· 0 citations
TL;DR
In this population-based cohort study, the five-year incidence of cancer following a new diagnosis of CVD was markedly high and the distribution of cancer types in this population differed from that of the general population, with a higher proportion of genitourinary cancers and a lower proportion of breast cancer.
Abstract
Patients with cardiovascular disease (CVD) have an increased risk of cancer, partly due to shared risk factors, chronic inflammation and systemic mediators. However, most previous studies have focused on individuals with pre-existing CVD. Whether patients with a new diagnosis of CVD are at particularly high risk of incident cancer, and whether the spectrum of cancer types differs from that of the general population, remains insufficiently explored.
To describe the five-year incidence of cancer in patients with a new diagnosis of CVD in our healthcare area and to compare the distribution of cancer types with that reported in the general population.
We conducted a population-based cohort study using clinical databases from our healthcare area. All adults (>18 years) without a previous history of cancer who were newly diagnosed with CVD between 2010 and 2022 were included. Incident cancers diagnosed between 3 months and 5 years after the index CVD diagnosis were recorded. The incidence and distribution of cancer types were analysed and compared with data from the general population.
A total of 9,900 patients with newly diagnosed CVD and no prior cancer history were identified. The mean age of the cohort was 64 years, 43% were women, and comorbidities were frequent. During follow-up, 1,922 patients (19.4%) developed incident cancer within five years. Patients who developed cancer were more often male, older, and had a higher burden of comorbidities than those who did not. Among CVD subtypes, chronic heart failure was associated with the highest risk of incident cancer. The most frequently diagnosed cancers were gastrointestinal (27%), lung (14.5%), genitourinary (13.5%) and male reproductive system cancers (13.4%).
In our healthcare area, the five-year incidence of cancer following a new diagnosis of CVD was markedly high. Moreover, the distribution of cancer types in this population differed from that of the general population, with a higher proportion of genitourinary cancers and a lower proportion of breast cancer. These findings highlight the importance of cancer awareness and surveillance strategies in patients with newly diagnosed CVD.Table.Basal characteristics. Figure.Types of incident cancer.
Patients with newly diagnosed CVD present a higher risk of cancer when compared to patients without a history of prior CVD, and men show a higher risk of incident cancer over time when patients with CVD are subclassified by biological sex, when patients with CVD are subclassified by biological sex.
H. Morillas Climent, P. Moliner, A. Ricarte-Marin et al.· European Heart Journal, Supp...· 0 citations
BACKGROUND AND AIMS
The incidence of cancer in people with cardiovascular disease (CVD) is poorly understood. This study aimed to understand the sex differences in incident cancer and cancer-related mortality in people with and without CVD.
METHODS
Participants were drawn from the European Prospective Investigation into Cancer (EPIC)-Norfolk study and followed up for a median of 26.2 years. Participants were stratified by sex and incident CVD during follow-up. Cumulative cancer incidence was calculated for each group. Sex-specific lifetime risks of cancer were determined, accounting for competing risks of death. Cause-specific hazard ratios (HRs) were determined using Royston-Parmar models, adjusted for ethnicity and time-updated covariates, including deprivation index, cardiovascular risk factors, comorbidities, and medication. Participants' CVD status was updated throughout follow-up.
RESULTS
A total of 22 534 participants were cancer-free at baseline (57% women; mean age 58.6 ± 9.3 and 59.5 ± 9.3 for women and men, respectively); 10 889 participants either had prevalent CVD at baseline or developed CVD during follow-up. Men had more comorbidities. The adjusted lifetime risk of incident cancer in CVD participants at age 75 was higher in men (17.3%) than in women (12.8%), with a significant cause-specific HR of 1.39 (99% confidence interval [CI] 1.25-1.53, P < .0001). Corresponding data for participants with no CVD were 10.2% for men and 8.2% for women, with an HR of 1.27 (99% CI 1.15-1.41, P < .0001 for men vs women). A similar trend exists for cancer-related mortality (HR 1.51, 99% CI 1.31-1.75, P < .0001 for men with CVD and HR 1.31, 99% CI 1.14-1.50, P < .0001 for men without CVD).
CONCLUSIONS
This study showed an increased lifetime cancer risk and mortality in men compared with women, which was mediated by comorbid CVD.
R. Thuemmler, T. Pana, M. Mamas et al.· European Heart Journal· 0 citations
Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.
V. Dvorovy, L. Kováčová, M. Selvek et al.· European Heart Journal, Supp...· 0 citations
The burden of pre-existing CVD at cancer diagnosis has increased substantially over the past two decades in the UK and is projected to rise further, highlighting the growing need for integrated prevention strategies and cardio-oncology services to address increasing multimorbidity in patients with cancer.
A. Alshahrani, E. Kontopantelis, C. Morgan et al.· European Heart Journal, Supp...· 0 citations
BACKGROUND AND AIMS
Advances in cancer care have improved survival, increasing the importance of comorbidities at diagnosis for longer-term outcomes. Pre-existing cardiovascular disease (CVD) can complicate management and prognosis, yet its long-term trends and future burden at cancer diagnosis are unclear. This study aimed to quantify temporal trends in pre-existing CVD among patients with newly diagnosed cancer and project prevalence through 2050.
METHODS
Linked primary care, cancer registry, and hospitalization records were used to identify 773 590 adults (≥18 years) diagnosed with the five most common cancers between 2001 and 2020 in England. Serial cross-sectional analyses estimated annual crude and age-standardized prevalence of pre-existing CVD and comorbidities. Temporal trends were assessed using logistic regression adjusted for demographics and cancer type. The contributions of changes in risk factor domains were evaluated using sequential modelling, and CVD prevalence was projected to 2050 using demographic-adjusted spline models.
RESULTS
The age-standardized prevalence of pre-existing CVD rose from 31.4% [95% confidence interval (CI) 31.2-31.6] in 2001-2005 to 39.2% (95% CI 39.0-39.4) in 2016-2020, with the steepest increases in lung and haematological cancers. Valvular disease, heart failure, atrial fibrillation, and diabetes showed the largest subtype rises. Sequential modelling showed the greatest attenuation of the temporal trend after adjustment for cardiometabolic conditions and chronic comorbidities. Projection analyses suggest that, if current temporal patterns continue, approximately half of patients may present with pre-existing CVD at cancer diagnosis by 2050.
CONCLUSIONS
Pre-existing CVD at cancer diagnosis has increased substantially over 2 decades and is projected to affect nearly half of patients by 2050. These trends underscore the need for the expansion of cardio-oncology services.
A. Alshahrani, E. Kontopantelis, C. Morgan et al.· European Heart Journal· 0 citations
Abstract Background Cancer and stroke are major causes of morbidity and mortality, with an increasing shared burden. This study aimed to provide population‐based estimates of ischemic stroke (IS) risk after cancer diagnosis across multiple cancer sites and demographic subgroups. Methods A retrospective cohort study was conducted linking the Israel National Cancer and Stroke Registries. Residents ≥40 years old diagnosed with first invasive cancer during 2014–2021 were followed for first‐ever IS within 1 year. IS risk was assessed using standardized incidence ratios (SIRs) and analyzed by cancer site, time since diagnosis, cancer stage, and demographic subgroups. One‐year cumulative incidence was estimated with death as a competing event. Results Among 182,221 patients, the SIR for IS within 1 year after cancer diagnosis was 1.8 (95% confidence interval [CI], 1.7–1.9). Risk peaked during the first 3 months (SIR, 2.5; 95% CI, 2.2–2.7). The highest SIRs were observed for pancreatic (SIR, 5.9; 95% CI, 4.8–7.3) and lung (SIR, 3.9; 95% CI, 3.4–4.4) cancers. SIRs decreased with age from 3.6 (95% CI, 2.8–4.6) among adults 40–54 years old to 1.4 (95% CI, 1.3–1.6) among those ≥75 years old. SIRs increased with stage, from 1.2 (95% CI, 1.0–1.4) in localized disease to 2.8 (95% CI, 2.5–3.2) in metastatic disease. One‐year cumulative incidence of IS was 0.62%, ranging from 0.30% in breast cancer to 1.62% in pancreatic cancer. Conclusions The early period after cancer diagnosis represents a critical window of increased IS risk. Incorporating targeted cerebrovascular risk assessment into oncologic care may facilitate earlier identification of high‐risk subgroups and support tailored prevention strategies.
C. Libruder, D. Tanne, B. Silverman et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
